The study focuses on postpartum depression, a type of depression that can occur after childbirth. The treatment being studied is a short-term use of the female sex hormone estradiol, which is delivered through a transdermal patch called Vivelle Dot. This patch releases a controlled amount of estradiol into the body over a 24-hour period. The study also involves a placebo, which is a substance with no active medication, to compare the effects of estradiol.
The purpose of the study is to see if using estradiol shortly after giving birth can help prevent depressive episodes in women who have previously experienced postpartum depression. Participants will receive either the estradiol patch or the placebo for a short period, from the day of birth up to 21 days postpartum. The study will monitor the participants for signs of depression from two weeks to six months after giving birth.
This research aims to provide insights into whether estradiol can be an effective strategy to prevent postpartum depression in women who are at high risk. By comparing the outcomes between those using the estradiol patch and those using the placebo, the study seeks to determine the potential benefits of this hormone treatment in managing postpartum mental health.



Denmark